Gene-Guided cocktail aims to outsmart tough lymphoma

NCT ID NCT06803693

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding drugs tailored to a patient's tumor genetics can improve standard chemotherapy for untreated diffuse large B-cell lymphoma. About 152 adults with intermediate-to-high risk disease will receive either the standard Pola-RCHP regimen or a version with extra targeted agents. The main goal is to see if the personalized combo delays cancer progression or relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone, and genotype-guided targeted agents
What this could lead to: If successful, this could lead to a more personalized treatment approach for DLBCL, potentially improving how long patients stay cancer-free.
What could go wrong: This is a phase 2 trial with only 152 participants, so results are preliminary. The added drugs may increase side effects without clear benefit, and the approach may not work for all genetic subtypes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Ruijin Hospital, Shanghai JiaoTong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.